Important intrinsic factor for the defence against hepatitis B viruses identified – consequences for treatment?
Around 350 million people are chronically infected with the hepatitis B virus world-wide. This is related to a markedly increased risk of liver cancer and liver cirrhosis. Researchers of the Paul-Ehrlich-Institut have discovered an intrinsic cellular factor, SAMHD1, which is upregulated by interferons and inhibits the hepatitis B infection.
Why is the immune system unable to combat HIV? Key factor identified
An international research group with essential participation of the Paul-Ehrlich-Institut, has identified NLRX1, a cellular factor of the human cell that is indispensable to the replication of Human Immunodeficiency Virus (HIV-1). This factor plays a key role in attenuating the innate immune system towards HIV-1. Until now, the significance of NLRX1 for the replication of HIV-1 and the attenuation of the immune system was not known. The novel research finding will lead to new therapeutic approaches.
Mouse model suitable for predicting cytokine storm by antibodies such as TGN1412
Researchers of the Paul-Ehrlich-Institut have developed a humanised mouse model that can be used to predict severe adverse immune reactions after administration of the monoclonal antibody TGN1412. A few years ago, the antibody led to severe immune reactions as a result of a cytokine storm in a clinical trial with healthy volunteers.